1.World Health Organization.(2018). Global Tuberculosis Report 2018. World Health Organization, Geneva. 277 pp.
2.Renwick, A. R., P. C. White, and R. G. Bengis, Bovine tuberculosis in southern African wildlife: a multi-species host-pathogen system. Epidemiol Infect, 2007. 135(4): p. 529–40.
3.Flynn, J. L. and J. Chan, Immunology of Tuberculosis. Annual Review of Immunology, 2001. 19(1): p. 93–129.
4.North, R. J. and Y.-J. Jung, Immunity to Tuberculosis. Annual Review of Immunology, 2004. 22(1): p. 599–623.
5.Cooper, A.M., Cell-Mediated Immune Responses in Tuberculosis. Annual Review of Immunology, 2009. 27(1): p. 393–422.
6.O’Garra, A., et al., The Immune Response in Tuberculosis. Annual Review of Immunology, 2013. 31(1): p. 475–527.
7.Pestka, S., C. D. Krause, and M. R. Walter, Interferons, interferon-like cytokines, and their receptors. Immunological Reviews, 2004. 202(1): p. 8–32.
8.Ivashkiv, L. B. and L. T. Donlin, Regulation of type I interferon responses. Nat Rev Immunol, 2014. 14(1): p. 36–49.
9.Piehler, J., et al., Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunological Reviews, 2012. 250(1): p. 317–334.
10.Berry, M. P., et al., An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature, 2010. 466(7309): p. 973–7.
11.Esmail, H., et al., Complement pathway gene activation and rising circulating immune complexes characterize early disease in HIV-associated tuberculosis. Proceedings of the National Academy of Sciences, 2018. 115(5): p. E964.
12.Singhania, A., et al., A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection. bioRxiv, 2017: p. 216879.
13.Wang, J., et al., Expression pattern of interferon-inducible transcriptional genes in neutrophils during bovine tuberculosis infection. DNA Cell Biol, 2013. 32(8): p. 480–6.
14.Manca, C., et al., Virulence of a <em>Mycobacterium tuberculosis</em> clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β. Proceedings of the National Academy of Sciences, 2001. 98(10): p. 5752.
15.Manca, C., et al., Hypervirulent M. tuberculosis W/Beijing Strains Upregulate Type I IFNs and Increase Expression of Negative Regulators of the Jak-Stat Pathway. Journal of Interferon & Cytokine Research, 2005. 25(11): p. 694–701.
16.Ordway, D., et al., The Hypervirulent <em>Mycobacterium tuberculosis</em> Strain HN878 Induces a Potent TH1 Response followed by Rapid Down-Regulation. The Journal of Immunology, 2007. 179(1): p. 522.
17.Carmona, J., et al., Mycobacterium tuberculosis Strains Are Differentially Recognized by TLRs with an Impact on the Immune Response. PLoS One, 2013. 8(6): p. e67277.
18.Antonelli, L. R., et al., Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest, 2010. 120(5): p. 1674–82.
19.Dorhoi, A., et al., Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics. Eur J Immunol, 2014. 44(8): p. 2380–93.
20.Mayer-Barber, K. D., et al., Host-directed therapy of tuberculosis based on interleukin–1 and type I interferon crosstalk. Nature, 2014. 511(7507): p. 99–103.
21. Hussain, T., et al., MicroRNA 27a–3p Regulates Antimicrobial Responses of Murine Macrophages Infected by Mycobacterium avium subspecies paratuberculosis by Targeting Interleukin–10 and TGF-beta-Activated Protein Kinase 1 Binding Protein 2. J. Front. Immunol. 2017, 8, 1915.
22.Cooper, A.M., et al., Disseminated tuberculosis in interferon gamma gene-disrupted mice. The Journal of Experimental Medicine, 1993. 178(6): p. 2243.
23.Flynn, J. L., et al., Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in mice. Immunity, 1995. 2(6): p. 561–572.
24.Cooper, A.M., et al., The role of interleukin–12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology, 1995. 84(3): p. 423–432.
25.Davis, J. M. and L. Ramakrishnan, The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell, 2009. 136(1): p. 37–49.
26.Bold, T. D. and J. D. Ernst, Who benefits from granulomas, mycobacteria or host? Cell, 2009. 136(1): p. 17–19.
27.Ottenhoff, T. H. M., et al., Genome-Wide Expression Profiling Identifies Type 1 Interferon Response Pathways in Active Tuberculosis. PLOS ONE, 2012. 7(9): p. e45839.
28.Stanley, S. A., et al., The Type I IFN Response to Infection with Mycobacterium tuberculosis Requires ESX–1-Mediated Secretion and Contributes to Pathogenesis. The Journal of Immunology, 2007. 178(5): p. 3143–3152.
29.Wu, K., et al., An Interferon-Related Signature in the Transcriptional Core Response of Human Macrophages to Mycobacterium tuberculosis Infection. PLOS ONE, 2012. 7(6): p. e38367.
30.McNab, F. W., et al., TPL–2-ERK1/2 signaling promotes host resistance against intracellular bacterial infection by negative regulation of type I IFN production. J Immunol, 2013. 191(4): p. 1732–43.
31.Dauphinee, S. M., et al., Contribution of increased ISG15, ISGylation and deregulated type I IFN signaling in Usp18 mutant mice during the course of bacterial infections. Genes Immun, 2014. 15(5): p. 282–92.
32.Mayer-Barber, Katrin D., et al., Innate and Adaptive Interferons Suppress IL–1α and IL–1β Production by Distinct Pulmonary Myeloid Subsets during Mycobacterium tuberculosis Infection. Immunity, 2011. 35(6): p. 1023–1034.
33.Mayer-Barber, K. D., et al., Caspase–1 independent IL–1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol, 2010. 184(7): p. 3326–30.
34.McNab, F. W., et al., Type I IFN induces IL–10 production in an IL–27-independent manner and blocks responsiveness to IFN-gamma for production of IL–12 and bacterial killing in Mycobacterium tuberculosis-infected macrophages. J Immunol, 2014. 193(7): p. 3600–12.
35.de Paus, R. A., et al., Inhibition of the type I immune responses of human monocytes by IFN-alpha and IFN-beta. Cytokine, 2013. 61(2): p. 645–55.
36.Teles, R. M. B., et al., Type I Interferon Suppresses Type II Interferon–Triggered Human Anti-Mycobacterial Responses. Science, 2013. 339(6126): p. 1448.
37.Bloom, C. I., et al., Transcriptional Blood Signatures Distinguish Pulmonary Tuberculosis, Pulmonary Sarcoidosis, Pneumonias and Lung Cancers. PLOS ONE, 2013. 8(8): p. e70630.
38.Panteleev, A. V., et al., Severe Tuberculosis in Humans Correlates Best with Neutrophil Abundance and Lymphocyte Deficiency and Does Not Correlate with Antigen-Specific CD4 T-Cell Response. Frontiers in Immunology, 2017. 8: p. 963.
39.Eruslanov, E. B., et al., Neutrophil responses to Mycobacterium tuberculosis infection in genetically susceptible and resistant mice. Infection and immunity, 2005. 73(3): p. 1744–1753.
40.Murray, P. J. and T. A. Wynn, Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol, 2011. 11(11): p. 723–37.
41.Bénard, A., et al., B Cells Producing Type I IFN Modulate Macrophage Polarization in Tuberculosis. American journal of respiratory and critical care medicine, 2018. 197(6): p. 801–813.
42.Troegeler, A., et al., C-type lectin receptor DCIR modulates immunity to tuberculosis by sustaining type I interferon signaling in dendritic cells. Proceedings of the National Academy of Sciences, 2017. 114(4): p. E540.
43.Boivin, N., et al., Interferon-β Suppresses Murine Th1 Cell Function in the Absence of Antigen-Presenting Cells. PLOS ONE, 2015. 10(4): p. e0124802.
44.Kavrochorianou, N., M. Markogiannaki, and S. Haralambous, IFN-beta differentially regulates the function of T cell subsets in MS and EAE. Cytokine Growth Factor Rev, 2016. 30: p. 47–54.
45.Gautier, G., et al., A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin–12p70 secretion by dendritic cells. J Exp Med, 2005. 201(9): p. 1435–46.
46.Proietti, E., et al., Type I IFN as a Natural Adjuvant for a Protective Immune Response: Lessons from the Influenza Vaccine Model. The Journal of Immunology, 2002. 169(1): p. 375–383.
47.Le Bon, A., et al., Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo. Immunity, 2001. 14(4): p. 461–470.